Suggested Learning

Xultophy approved for renal impairment

The European Commission recently approved Xultophy (insulin degludec plus liraglutide) for adults with type 2 diabetes and moderate renal impairment (creatinine clearance 30-59ml/min). Up to 40 per cent of people with type 2 diabetes develop some degree of renal impairment.

Latest discussions

  1. Pre reg exams

    Thanks for your comments both - Richard ...

  2. Pre reg exams

    Having been qualified just over 40 years...

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.